News | December 17, 2025
Gujarat Kidney and Super Speciality to file IPO at Rs.108- Rs.114 per share
The company operates a chain of mid-sized multi-speciality hospitals
The company operates a chain of mid-sized multi-speciality hospitals
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The company had achieved the highest "A" rating in Climate Change
Subscribe To Our Newsletter & Stay Updated
